AIM ImmunoTech is a Florida-based immuno-pharma company engaged in the research and development of therapeutics targeting cancers, viral diseases, and immune-deficiency disorders. The company operates two marketed products: Ampligen (rintatolimod), a macromolecular double-stranded RNA therapeutic approved for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa-n3), a naturally-sourced alpha interferon product indicated for genital warts treatment. The company's pipeline includes Ampligen formulations under development for multiple cancer indications spanning pancreatic, renal cell, lung, ovarian, breast, colorectal, and prostate cancers, as well as viral conditions including Hepatitis B, HIV, and COVID-19-related disorders.
The company was incorporated in Delaware in 1966 and operated under the name Hemispherx Biopharma before rebranding to AIM ImmunoTech in August 2019. Its primary operations are headquartered in Ocala, Florida. The organization is relatively small, with a workforce of 21 full-time employees, consistent with an early-to-mid stage biopharmaceutical developer focused on clinical and preclinical programs rather than commercial-scale manufacturing or distribution. AIM ImmunoTech is listed on the NYSE.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.31 | $-0.31 | +48.3% | |
| 2023 | $-0.60 | $-0.60 | -50.0% | |
| 2022 | — | $-0.40 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-27 | 0001641172-25-000847 | SEC ↗ |
| 2023-12-31 | 2024-04-01 | 0001493152-24-012058 | SEC ↗ |
| 2022-12-31 | 2023-03-31 | 0001493152-23-010351 | SEC ↗ |
| 2021-12-31 | 2022-03-31 | 0001493152-22-008324 | SEC ↗ |
| 2020-12-31 | 2021-03-31 | 0001493152-21-007259 | SEC ↗ |
| 2019-12-31 | 2020-03-30 | 0001493152-20-005290 | SEC ↗ |
| 2018-12-31 | 2019-04-01 | 0001493152-19-004583 | SEC ↗ |
| 2017-12-31 | 2018-03-30 | 0001493152-18-004291 | SEC ↗ |
| 2016-12-31 | 2017-03-31 | 0001493152-17-003242 | SEC ↗ |
| 2015-12-31 | 2016-03-29 | 0001615774-16-004671 | SEC ↗ |
| 2014-12-31 | 2015-03-19 | 0000946644-15-000008 | SEC ↗ |
| 2013-12-31 | 2014-03-14 | 0000946644-14-000005 | SEC ↗ |
| 2012-12-31 | 2013-03-18 | 0001144204-13-015749 | SEC ↗ |